Our October 1, 2026 source check found no mazdutide approval record in the FDA's public Drugs@FDA data and no verified U.S. approval date. Innovent has announced approval in China. Those are different jurisdictions and different milestones.
The evidence by jurisdiction
| Jurisdiction | What the source establishes |
|---|---|
| China | Innovent's June 2026 announcement reports NMPA approval for adult weight management and adult type 2 diabetes. |
| United States | The FDA drug-approval data query for active ingredient MAZDUTIDE returned no matching record. |
Innovent announcement, June 6, 2026 is the source for the Chinese indications. FDA Drugs@FDA data documentation describes the U.S. approval dataset used for this check. A no-match result is a source observation, not a predicted regulatory decision.
Why a trial date is not an approval date
Lilly's NCT06124807 identifies a phase 2 study of LY3305677, another development name for mazdutide. Trial completion, submission of an application, and FDA approval are separate events.
Can we give a U.S. launch date?
No verified date follows from the sources above. A Chinese approval or a U.S. trial record does not establish a U.S. launch schedule. This page will need a substantive update when an FDA approval record or a dated sponsor announcement establishes a new milestone.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →What mazdutide is
Mazdutide targets GLP-1 and glucagon receptors. Its development names include IBI362 and LY3305677. Matching those names matters when searching trial and approval records so that a change in terminology is not mistaken for a different drug.
Can this page replace medical advice about Mazdutide?
No. Mazdutide Us Approval is informational. A licensed clinician who knows your history should review contraindications, labs, medication fit, and dose decisions.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →